This IL-6 enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific to IL-6. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for IL-6 and incubated. IL-6, if present, will bind and become immobilized by the antibody pre-coated on the wells and then be “sandwiched” by biotin conjugate. The microtiter plate wells are thoroughly washed to remove unbound IL-6 and other components of the sample. In order to quantitatively determine the amount of IL-6 present in the sample, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Avidin is a tetramer containing four identical subunits that each has a high affinity-binding site for biotin. The wells are thoroughly washed to remove all unbound HRP-conjugated Avidin and a TMB (3,3'5, 5' tetramethyl-benzidine) substrate solution is added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain IL-6, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in colour. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the colour change is measured spectrophotometrically at a wavelength of 450nm ± 2 nm.

In order to measure the concentration of IL-6 in the samples this kit includes two calibration diluents (Calibrator Diluent I for serum/plasma testing and Calibrator Diluent II for cell culture supernatant testing.) According to the testing system, the provided standard is diluted (2-fold) with the appropriate Calibrator Diluent and assayed at the same time as the samples. This allows the operator to produce a standard curve of Optical Density (O.D) versus IL-6 concentration (pg/mL). The concentration of IL-6 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Piattaforma

Microplate

Tipo di rilevamento

Colorimetric

Tipo di campione

Serum, plasma, cell culture supernatant, and other biological fluids.

Sensibilità

< 7 pg/ml

Campo di rilevamento

7-2000 pg/ml

Tempo del kit

3h 30m

Specificità

This sandwich ELISA recognizes both natural and recombinant human IL-6.

Reattività

Human

Reattività incrociata

This assay has shown no cross reactivity with various other cytokines superfamily proteins.

Precision

Intra-assay CV: < 8%, Inter-assay CV: < 10%

Conservazione

Store at 2-8°C.

Sinonimi

B cell differentiation factor , B cell stimulatory factor 2, B-cell stimulatory factor 2, BSF 2, BSF-2, BSF2, CDF, CTL differentiation factor, Cytotoxic T cell differentiation factor , Hepatocyte stimulating fact, Hepatocyte stimulating factor, Hepatocyte stimulatory factor, HGF, HPGF, HSF , Hybridoma growth factor, Hybridoma growth factor Interferon beta-2, Hybridoma plasmacytoma growth factor , IFN-beta-2, IFNB2 , IL 6, IL-6, IL6, IL6 protein , IL6_HUMAN, Interferon beta 2, Interferon beta-2, Interleukin 6, Interleukin 6 (interferon beta 2) , Interleukin BSF 2, Interleukin BSF2, Interleukin6

Dichiarazione di non responsabilità

Questo prodotto è solo per uso di ricerca. Non è inteso per uso diagnostico o terapeutico.

Pubblicazioni (1)

Visualizza pubblicazione

Enhanced insulin sensitivity in prepubertal children with constitutional delay of growth and development.

Riferimenti: Human Interleukin-6 ELISA Kit (A33008)

Astratto:

OBJECTIVE:

To test the hypothesis that prepubertal children with presumed constitutional delay of growth and development (CDGD) have enhanced insulin sensitivity and, therefore, insulin sensitivity is associated with later onset of puberty.

STUDY DESIGN:

Twenty-one prepubertal children with presumed CDGD and 23 prepubertal control children, underwent a frequently sampled intravenous glucose tolerance test to evaluate insulin sensitivity and other markers of insulin, glucose, and growth regulation.

RESULTS:

Children in the CDGD group were shorter and leaner than control subjects. Children with presumed CDGD were 40% more insulin sensitive (17.0 x 10(-4) min(-1)/[mU/L] versus 12.1 x 10(-4) min(-1)/[mU/L]; P = .0006) and had reduced acute insulin response, thus maintaining euglycemia (216 mU/L versus 330 mU/L; P = .02) compared with control subjects. In addition, the CDGD group had lower serum insulin-like growth factor binding protein 3 levels (3333 ng/mL versus 3775 ng/mL; P = .0004) and a trend toward lower serum insulin-like growth factor-II levels (794 ng/mL versus 911 ng/mL; P = .06).

CONCLUSION:

Prepubertal children with presumed CDGD have enhanced insulin sensitivity, supporting the hypothesis that insulin sensitivity is associated with timing of puberty. It may signify long-term biological advantages with lower risk of metabolic syndrome and malignancy.

Visualizza pubblicazione

Prodotti alternativi a Umano Interleukin-6 Kit Elisa (A33008)

A78324